Answers are grounded in this paper and cite their sources.
Background While much recent literature has focused on patients’ and families’ perceptions of the value of genome-wide sequencing (GS, including exome and genome sequencing) for rare disease diagnosis, conceptual and methodological limitations remain. We sought to characterize expectations of, and longitudinal perspectives on, the value of GS and its outcomes for parents of pediatric rare disease patients.Methods From December 2021 through April 2024, we enrolled and followed parents of pediatric patients undergoing GS with pending results. Parents completed three in-depth interviews: at baseline, at return of results, and six months after return. Data were analyzed using both qualitative and quantitative methods.Results Thirty-six parents participated. Four key findings emerged: 1) at baseline, parents balanced expansive hope for a range of benefits from GS with tempered expectations; 2) parents of children who received a definitive diagnosis reported achieving many expected outcomes, but the ultimate value of these outcomes was shaped by personal values and contextual factors; 3) parents of children who did not receive a definitive diagnosis nonetheless achieved some of the outcomes they sought from GS through other means; and 4) parents’ perceptions of the outcomes of sequencing evolved over time in varying directions.Conclusions Our findings indicate that the current literature examining the value parents ultimately derive from GS for rare disease diagnosis may fail to address critical nuances in subjective perceptions of value. Better understanding this value requires clarification of theories of value underlying current measures, rigorous, comparative methods, and consideration of families’ specific values and preferences.
No takes yet. Share an insight, caveat, or question.
Brassfield et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: